Pituitary Adenomas Drive Severe Central Adrenal Insufficiency in Over 90% of Patients: Study
A recent observational study published in the Indian Journal of Endocrinology and Metabolism in June 2025 reveals that pituitary adenomas are the leading cause of a severe, frequently overlooked endocrine disorder. Alarmingly, the research highlights that a staggering 90.5% of affected patients face profound central adrenal insufficiency.
To address the severe lack of epidemiological data on hypopituitarism in India, Dr. Vinay R. Pandit and his team at AIIMS Raipur investigated the clinical profiles and causes of this serious hormonal disorder. The comprehensive study aims to bridge the current knowledge gap and highlight the urgent need for early medical diagnosis.
Therefore, researchers conducted a four-year observational study of 54 adult patients at a tertiary care hospital to evaluate the varying causes of hypopituitarism. They successfully diagnosed these hormone deficiencies by analyzing baseline clinical symptoms alongside targeted laboratory tests.
Key Clinical Findings of the Study Includes:
Predominant Symptoms: The most common initial presentation consisted of mass-effect symptoms, specifically headaches seen in 50% of the cohort and visual disturbances in 40.7%, which often overshadowed classical endocrine complaints.
Primary Etiologies: Pituitary adenomas constituted the foremost etiology at 42.6%, trailed by other sellar tumors at 33.3%, with a notable prevalence of patients acquiring postoperative pituitary insufficiency compared to preoperative diagnoses.
Endocrine Deficiencies: Deficient adrenocorticotropic hormone (ACTH) function emerged as the most widespread hormonal abnormality affecting 90.5% of subjects, followed closely by thyroid-stimulating hormone (TSH) reductions at 87%, while panhypopituitarism manifested in 59.2% of cases.
Maternal Impact: Sheehan’s syndrome remained a surprisingly prominent contributor in this demographic, accounting for 14.8% of cases, contrasting sharply with the minimal 0.5% incidence reported in retrospective Western cohorts.
Diagnostic Delay: Patients experienced a concerning overall median delay in diagnosis of 12 months, which extended dramatically to 18 months for those suffering from Sheehan’s syndrome compared to just 6 months for pituitary tumors.
The results suggest that hypopituitarism is characterized by highly diverse manifestations stemming predominantly from tumoral causes, demonstrating that non-specific initial complaints significantly contribute to prolonged diagnostic delays and mask life-threatening vulnerabilities like a 90.5% rate of central adrenal insufficiency.
Thus, the study concludes that practicing clinicians might find it beneficial to maintain an elevated index of clinical suspicion for covert pituitary dysfunction when evaluating adults who present with subtle, persistent mass-effect symptoms, as timely intervention with tailored hormone replacement therapy is pivotal to minimizing severe morbidity.
Because the study primarily analyzed initial hormone levels within a cross-sectional framework and lacked universal dynamic testing for diagnosing precise growth hormone (GH) deficits, it may be helpful for future longitudinal investigations to track prolonged post-treatment outcomes to gently guide the evolution of refined early-detection strategies.
Reference
Pandit VR, Pant K, Ghosh A, Kannauje PK, Meher J. Clinical profile of patients with hypopituitarism in a Tertiary Care Centre in Central India. Indian J Endocr Metab 2025;29:308-12.
